公开(公告)号：US20230257738A1

公开(公告)日：2023-08-17

申请号：US17933500

申请日：2022-09-20

Applicant: ModernaTX, Inc.

Inventor： Melissa J. MOORE ,  Caroline KÖHRER ,  Ruchi JAIN ,  Vladimir PRESNYAK

IPC: C12N15/11 ,  A61K47/69 ,  C12N15/85 ,  C12N15/88

CPC classification number: C12N15/11 ,  A61K47/6929 ,  C12N15/85 ,  C12N15/88 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335

Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.

公开(公告)号：US20210163928A1

公开(公告)日：2021-06-03

申请号：US17041332

申请日：2019-04-11

Applicant: ModernaTX, Inc.

Inventor： David REID ,  Caroline KÖHRER ,  Ruchi JAIN ,  Melissa J. MOORE ,  Scott DONOVAN ,  Aaron LARSEN ,  Vladimir PRESNYAK

IPC: C12N15/11 ,  A61K48/00 ,  C12Q1/6897

Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, in particular C-rich or CG-rich elements, which provide a desired translational regulatory activity to the mRNA.

公开(公告)号：US20210260097A1

公开(公告)日：2021-08-26

申请号：US17036374

申请日：2020-09-29

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20180256628A1

公开(公告)日：2018-09-13

申请号：US15761220

申请日：2016-10-05

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/127 ,  A61K9/00 ,  C12N15/113

CPC classification number: A61K31/7115 ,  A61K9/0019 ,  A61K9/127 ,  C12N15/113 ,  C12N15/67 ,  C12N2310/141 ,  C12N2800/107 ,  C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20230338410A1

公开(公告)日：2023-10-26

申请号：US18167984

申请日：2023-02-13

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

CPC classification number: A61K31/7115 ,  A61K9/0019 ,  A61K9/127 ,  C12N15/113 ,  C12N15/67 ,  C12N2310/141 ,  C12N2800/107 ,  C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20220387628A1

公开(公告)日：2022-12-08

申请号：US17618779

申请日：2020-06-24

Applicant: ModernaTX, Inc.

Inventor： Ruchi JAIN ,  David REID ,  Vladimir PRESNYAK ,  Alicia BICKNELL ,  Caroline KÖHRER

IPC: A61K48/00

Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide desirable regulation of mRNA localization, stability, and/or translation to yield increased mRNA expression and activity of an encoded polypeptide.

公开(公告)号：US20230086537A1

公开(公告)日：2023-03-23

申请号：US17608359

申请日：2020-05-07

Applicant: ModernaTX, Inc.

Inventor： Ruchi JAIN ,  Gilles BESIN ,  Elizaveta ANDRIANOVA

IPC: C12N15/88 ,  A61K31/7088

Abstract: The disclosure features mRNAs engineered with one or more microRNA binding sites targeted by a microRNA(s) that are differentially expressed in a target immune cell relative to a plurality of non-target immune cells. The disclosure also features methods of using the same, for example, for selectively degrading the mRNA in the target immune cell relative to the plurality of non-target immune cells.

公开(公告)号：US20200208145A1

公开(公告)日：2020-07-02

申请号：US16614245

申请日：2018-05-18

Applicant: MODERNATX, INC.

Inventor： Melissa J. MOORE ,  Caroline KÖHRER ,  Ruchi JAIN ,  Vladimir PRESNYAK

IPC: C12N15/11 ,  C12N15/85 ,  C12N15/88 ,  A61K47/69

Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.